These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 11443156

  • 1. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
    Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
    [Abstract] [Full Text] [Related]

  • 2. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
    Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP.
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
    [Abstract] [Full Text] [Related]

  • 3. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.
    Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4172-7. PubMed ID: 10566668
    [Abstract] [Full Text] [Related]

  • 4. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
    Frajese GV, Taylor NF, Jenkins PJ, Besser GM, Monson JP.
    Horm Res; 2004 Nov; 61(5):246-51. PubMed ID: 15004437
    [Abstract] [Full Text] [Related]

  • 5. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Urinary steroid excretion rates in acromegaly.
    Vierhapper H, Nowotny P, Waldhäusl W.
    Horm Res; 2005 Aug; 63(5):234-7. PubMed ID: 15900108
    [Abstract] [Full Text] [Related]

  • 9. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ.
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
    Finken MJ, Andrews RC, Andrew R, Walker BR.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3316-21. PubMed ID: 10487705
    [Abstract] [Full Text] [Related]

  • 12. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
    Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ.
    Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
    [Abstract] [Full Text] [Related]

  • 13. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients.
    Toogood AA, Taylor NF, Shalet SM, Monson JP.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1727-30. PubMed ID: 10770221
    [Abstract] [Full Text] [Related]

  • 14. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
    Palermo M, Delitala G, Sorba G, Cossu M, Satta R, Tedde R, Pala A, Shackleton CH.
    J Endocrinol Invest; 2000 Apr; 23(7):457-62. PubMed ID: 11005270
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G.
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ.
    N Engl J Med; 2000 Apr 20; 342(16):1171-7. PubMed ID: 10770982
    [Abstract] [Full Text] [Related]

  • 18. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ.
    J Clin Endocrinol Metab; 2012 Apr 20; 97(4):1187-93. PubMed ID: 22278424
    [Abstract] [Full Text] [Related]

  • 19. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H.
    J Clin Endocrinol Metab; 2005 Oct 20; 90(10):5627-31. PubMed ID: 16046586
    [Abstract] [Full Text] [Related]

  • 20. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    Zgliczyński W, Zdunowski P.
    Endokrynol Pol; 2007 Oct 20; 58(5):408-16. PubMed ID: 18058736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.